Olmesartán/Amlodipino Sandoz (Olmesartan Medoxomil, Amlodipine Besilate)

Olmesartan medoxil and Amlodipine besilate, the active ingredients in Olmesartán/Amlodipino Sandoz, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adult patients, often when monotherapy does not achieve target control. GNH USA supplies Olmesartán/Amlodipino Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán/Amlodipino Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine is a fixed‑dose antihypertensive that acts on the renin‑angiotensin system and vascular smooth‑muscle tone. - Hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Hypertension with concomitant edema: reduces fluid retention while controlling pressure. - High‑risk cardiovascular patients: contributes to overall risk reduction as part of a comprehensive treatment plan.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angio‑edema: swelling of face, lips, tongue or airway. - Severe hypotension: markedly low blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Acute kidney injury: sudden decline in renal function. - Myocardial infarction: rare occurrence of heart attack. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing.

When prescribing Olmesartan/Amlodipine, clinicians should consider patient‑specific factors and monitor for adverse events. - Renal impairment: adjust monitoring and avoid rapid dose escalation. - Hepatic disease: use with caution and assess liver function periodically. - Pregnancy: contraindicated; drug may harm fetal development. - Concomitant potassium‑sparing diuretics: monitor serum potassium levels. - Elderly patients: start at lower dose and observe for orthostatic symptoms. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan/Amlodipine may interact with several drug classes; careful review is recommended. Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: concurrent ACE inhibitors or ARBs increases risk of hyperkalaemia and renal impairment. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise amlodipine levels. - Lithium: increased risk of lithium toxicity. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Diuretics: additive blood‑pressure lowering effect; monitor electrolytes. - Simvastatin: increased statin exposure; consider dose adjustment.